Tandem Diabetes Care, Inc.
HealthcareNASDAQ:TNDM · NASDAQ Global Market
+$0.80 today
Vol 1.75M · Avg 2.36M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.0B of revenue converted into -$94.5M of net income for the selected period. Gross margin is 54.8% and net margin is -9.7%, showing how much revenue survives after costs and taxes. EPS is $-1.40, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B +7.9% | $940.2M +25.7% | $747.7M -6.7% | $801.2M +14.0% | $702.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $483.9M +7.4% | $450.6M +18.6% | $380.0M -2.1% | $388.2M +18.9% | $326.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $530.8M +8.4% | $489.6M +33.1% | $367.7M -11.0% | $413.0M +9.8% | $376.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 52.3% +0.2pp | 52.1% +2.9pp | 49.2% -2.4pp | 51.5% -2.0pp | 53.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $174.8M -12.1% | $198.9M -19.9% | $248.4M +46.0% | $170.2M +84.8% | $92.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $434.1M +11.4% | $389.8M +10.6% | $352.5M +5.0% | $335.7M +28.4% | $261.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $609.0M +3.4% | $588.7M -2.0% | $600.9M +18.8% | $505.8M +43.1% | $353.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $17.7M +11081.0% | $158.0K -99.0% | $15.7M +9.7% | $14.3M +3.5% | $13.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$174.7M -76.2% | -$99.1M +49.5% | -$196.5M -164.7% | -$74.2M -317.9% | $34.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -17.2% -6.7pp | -10.5% +15.7pp | -26.3% -17.0pp | -9.3% -14.1pp | 4.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$78.1M +21.2% | -$99.1M +57.5% | -$233.2M -151.2% | -$92.8M -509.9% | $22.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -7.7% +2.8pp | -10.5% +20.6pp | -31.2% -19.6pp | -11.6% -14.8pp | 3.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.1M -49.5% | $18.0M -21.3% | $22.9M +277.4% | $6.1M +798.7% | $674.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.9M +6.6% | $7.4M -25.0% | $9.9M +59.2% | $6.2M +2.8% | $6.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$122.2M -1783.2% | $7.3M -44.1% | $13.0M +324500.0% | -$4.0K +99.9% | -$6.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$200.3M -118.0% | -$91.9M +58.3% | -$220.3M -137.2% | -$92.9M -683.9% | $15.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -19.7% -10.0pp | -9.8% +19.7pp | -29.5% -17.9pp | -11.6% -13.9pp | 2.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $4.4M +6.8% | $4.2M +76.3% | $2.4M +35.3% | $1.7M +420.0% | $335.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$204.7M -113.2% | -$96.0M +56.9% | -$222.6M -135.3% | -$94.6M -707.7% | $15.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -20.2% -10.0pp | -10.2% +19.6pp | -29.8% -18.0pp | -11.8% -14.0pp | 2.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -106.8% | -$1 +57.1% | -$3 -133.3% | -$1 -688.0% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -106.8% | -$1 +57.1% | -$3 -133.3% | -$1 -712.5% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $67.3M +2.8% | $65.5M +0.8% | $64.9M +1.2% | $64.1M +1.8% | $63.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $67.3M +2.8% | $65.5M +0.7% | $65.0M +1.3% | $64.1M -0.3% | $64.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
InMode Ltd.
NASDAQ:INMD
$817.88M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TNDM generate?
Tandem Diabetes Care, Inc. (TNDM) reported $1.01B of revenue in fiscal 2025.
Is TNDM profitable?
Tandem Diabetes Care, Inc. (TNDM) reported -$204,710,000.00 of net income, with a net margin of -20.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.